Administration of the DuPont™ Danisco® Probiotic Strain BifidobacteriumAnimalis Subsp. Lactis420 (B420™) Reduces Weight Gain and Improves Glucose Tolerance, Thereby Counteracting the Adverse Effects of a High-fat Diet in Mice.
KANTVIK, Finland – A landmark probiotic study was carried out as part of collaboration between Professor Remy Burcelin, an internationally renowned expert of glucose metabolism and research director at the National Institute of Health & Medical Research (INSERM) in Toulouse, France, and the DuPont Nutrition & Health Research Centre in Kantvik, Finland.
“These new results confirm previous animal study results and show that B420™ may have an effect on weight and body composition, as well as on the development of metabolic diseases, such as insulin resistance” said SampoLahtinen, active nutrition technology leader of DuPont Nutrition &Health, Kantvik.
The Action of BifidobacteriumLactis420™
[wp_ad_camp_3]The selected probiotic strain, Bifidobacteriumlactis 420™, is a naturally occurring strain, originally isolated from dairy products. The strain has been studied by the Active Nutrition Research Group of DuPont Nutrition &Health over a period of many years, mainly focusing on its anti-inflammatory properties and more recently on its effect on metabolism.
The researchers used two high-fat diet models: obese mice with metabolic disorders, or diabetic mice. The probiotic strain B420™ was demonstrated to drastically reduce body fat mass, as well as to improve glucose tolerance which was impaired in these mouse models. Importantly, B420™ treatment reduced liver inflammatory markers in the diabetic mice to the level of healthy control mice. The liver is one of the most important organs controlling metabolism and has a central role in the development of obesity-related metabolic diseases. Thereby this finding indicates that probiotic treatment may have further wide-spread effects on metabolism. Intestinal mechanisms were explored in the diabetic mouse model where B420™ was shown to reduce adhesion of certain pathogenic bacteria onto the small intestinal mucosa. These bacteria hold a highly inflammatory surface molecule called lipopolysaccharide (LPS). Elevated blood LPS concentration, i.e. metabolic endotoxemia, is blamed by many scientists for low-grade inflammation, insulin resistance, and even obesity. Strikingly, B420™also was able to completely normalize plasma lipopolysaccharide (LPS) levels in diabetic mice.
Developing a New Area of Expertise
Obesity, fatty liver and insulin resistance are part of the so-called cardiometabolic syndrome (metabolic syndrome, syndrome-x) which has been increasingly linked to an imbalance (dysbiosis) of the intestinal microbiota. This finding implies that probiotics and prebiotics could potentially help fight obesity and its related metabolic disorders when those disorders are related to a dysbiosis of the gut microbiota, and must be further investigated.
“We strongly believe that this new research area may open up new opportunities for probiotics in functional foods in the future and we have developed a research program on the effects of probiotics on metabolic diseases,” said Martin Kullen, health and protection technology leader of DuPont Nutrition & Health.
DuPont (NYSE: DD) has been bringing world-class science and engineering to the global marketplace in the form of innovative products, materials, and services since 1802. The company believes that by collaborating with customers, governments, NGOs and thought leaders, we can help find solutions to such global challenges as providing enough healthy food for people everywhere, decreasing dependence on fossil fuels, and protecting life and the environment. For additional information about DuPont and its commitment to inclusive innovation, please contact with them.
All of the information provided in this press release is of DuPont, does not necessarily represent the official views or policies of the Pharma Mirror Magazine.